Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar 18;14(6):1569.
doi: 10.3390/cancers14061569.

The New Treatment Methods for Non-Hodgkin Lymphoma in Pediatric Patients

Justyna Derebas  1 , Kinga Panuciak  1 , Mikołaj Margas  1 , Joanna Zawitkowska  2 , Monika Lejman  3
Affiliations
Review

The New Treatment Methods for Non-Hodgkin Lymphoma in Pediatric Patients

Justyna Derebas et al. Cancers (Basel). .

Abstract

One of the most common cancer malignancies is non-Hodgkin lymphoma, whose incidence is nearly 3% of all 36 cancers combined. It is the fourth highest cancer occurrence in children and accounts for 7% of cancers in patients under 20 years of age. Today, the survivability of individuals diagnosed with non-Hodgkin lymphoma varies by about 70%. Chemotherapy, radiation, stem cell transplantation, and immunotherapy have been the main methods of treatment, which have improved outcomes for many oncological patients. However, there is still the need for creation of novel medications for those who are treatment resistant. Additionally, more effective drugs are necessary. This review gathers the latest findings on non-Hodgkin lymphoma treatment options for pediatric patients. Attention will be focused on the most prominent therapies such as monoclonal antibodies, antibody-drug conjugates, chimeric antigen receptor T cell therapy and others.

Keywords: aggressive non-Hodgkin lymphoma; children and adolescents; non-Hodgkin lymphoma.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Structure of CAR-T cells and their antitumor function.
Figure 2
Figure 2
Effect of DMNT inhibitors application.
Figure 3
Figure 3
Mechanism of action HDACI.
Figure 4
Figure 4
Construction of the CAR-T cell.
Figure 5
Figure 5
Signalling pathways blocked by ALK inhibitors.
Figure 6
Figure 6
Bortezomib mechanism of action.
See this image and copyright information in PMC

References

    1. Moubadder L., McCullough L.E., Flowers C.R., Koff J.L. Linking Environmental Exposures to Molecular Pathogenesis in Non-Hodgkin Lymphoma Subtypes. Cancer Epidemiol. Biomark. Prev. 2020;29:1844–1855. doi: 10.1158/1055-9965.EPI-20-0228. - DOI - PMC - PubMed
    1. Harker-Murray P.D., Pommert L., Barth M.J. Novel Therapies Potentially Available for Pediatric B-Cell Non-Hodgkin Lymphoma. J. Natl. Compr. Cancer Netw. 2020;18:1125–1134. doi: 10.6004/jnccn.2020.7608. - DOI - PubMed
    1. Tsuyama N., Sakamoto K., Sakata S., Dobashi A., Takeuchi K. Anaplastic Large Cell Lymphoma: Pathology, Genetics, and Clinical Aspects. J. Clin. Exp. Hematop. 2017;57:120–142. doi: 10.3960/jslrt.17023. - DOI - PMC - PubMed
    1. Reedijk A.M.J., Beishuizen A., Coebergh J.W., Hoeben B.A.W., Kremer L.C.M., Hebeda K.M., Pieters R., Loeffen J.L.C., Karim-Kos H.E. Progress against Non-Hodgkin′s Lymphoma in Children and Young Adolescents in the Netherlands since 1990: Stable Incidence, Improved Survival and Lower Mortality. Eur. J. Cancer. 2022;163:140–151. doi: 10.1016/j.ejca.2021.12.010. - DOI - PubMed
    1. Sandlund J.T., Martin M.G. Non-Hodgkin lymphoma across the pediatric and adolescent and Young Adult Age Spectrum. Hematol. Am. Soc. Hematol. Educ. Progr. 2016;2016:589–597. doi: 10.1182/asheducation-2016.1.589. - DOI - PMC - PubMed

LinkOut - more resources